000304988 001__ 304988
000304988 005__ 20251001115232.0
000304988 0247_ $$2doi$$a10.1097/MPA.0000000000002553
000304988 0247_ $$2pmid$$apmid:41001906
000304988 0247_ $$2ISSN$$a0885-3177
000304988 0247_ $$2ISSN$$a1536-4828
000304988 037__ $$aDKFZ-2025-01979
000304988 041__ $$aEnglish
000304988 082__ $$a610
000304988 1001_ $$0P:(DE-He78)6e9ce2232245f76dc483333cba4a5b91$$aThiel, Vera$$b0$$eFirst author$$udkfz
000304988 245__ $$aProteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC.
000304988 260__ $$aPhiladelphia, Pa.$$bLippincott Williams & Wilkins$$c2025
000304988 3367_ $$2DRIVER$$aarticle
000304988 3367_ $$2DataCite$$aOutput Types/Journal article
000304988 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1759230688_31255
000304988 3367_ $$2BibTeX$$aARTICLE
000304988 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304988 3367_ $$00$$2EndNote$$aJournal Article
000304988 500__ $$a#EA:A010#LA:A010# / epub
000304988 520__ $$aTo investigate the proteomic profile of different molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) and understand their impact on patient outcomes, particularly focusing on pathways involved in xenobiotic metabolism and drug resistance.The study utilized the serum-free PACO cell culture model and a quantitative prefractionation-based MALDI/MS approach to establish the proteomic profiles of various PDAC subtypes. Differential protein regulation was analyzed to identify systematic alterations in metabolic and drug resistance pathways. Mechanistic studies involved the knockdown and overexpression of key proteins to assess their role in drug resistance.Proteomic analysis revealed subtype-specific alterations, particularly in pathways associated with xenobiotic metabolism and drug resistance. Notably, CYP2S1, a member of the CYP450 family, was upregulated in the HNF1A+ PDAC subtype. CYP2S1 levels were further inducible by polyaromatic hydrocarbons (PAHs) and SN38, the active metabolite of irinotecan via AHR. Mechanistic studies demonstrated that knockdown of AHR or CYP2S1 sensitized PDAC cells to SN38, whereas overexpression of CYP2S1 increased resistance to SN38.The findings highlight the significant role of CYP2S1 in mediating drug resistance in certain PDAC subtypes. Targeting CYP2S1 and its regulatory pathways could enhance the efficacy of chemotherapeutic agents like irinotecan in treating PDAC. These results provide new insights into the molecular mechanisms underlying PDAC subtype-specific drug resistance and suggest potential therapeutic targets.
000304988 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000304988 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304988 650_7 $$2Other$$aAHR
000304988 650_7 $$2Other$$aCYP2S1
000304988 650_7 $$2Other$$aGeLC-based MALDI/MS
000304988 650_7 $$2Other$$aMSQBAT
000304988 650_7 $$2Other$$aPDAC
000304988 7001_ $$0P:(DE-He78)067d470839d964b72671ab5d5e2d5a70$$aNadler, Wiebke$$b1$$eFirst author
000304988 7001_ $$0P:(DE-He78)c8c3731ac32efc10657108a8c8ae1fa6$$aKerner, Alexander$$b2$$udkfz
000304988 7001_ $$0P:(DE-He78)cdce23b98212f4c0ae5f2c63cf14d9ee$$aKuhlmann, Laura$$b3
000304988 7001_ $$0P:(DE-He78)fdbfe09d9e673c78880ead1e0a7a2063$$aReitberger, Manuel$$b4
000304988 7001_ $$0P:(DE-He78)7a92d9b96e406e0b3e2444b4383c4dc5$$aVorberg, Tim$$b5$$udkfz
000304988 7001_ $$0P:(DE-He78)8a03c8dd68c79f91bfe6594e4d2f97e2$$aSchwerd-Kleine, Paul$$b6$$udkfz
000304988 7001_ $$0P:(DE-He78)19623ddc45d1abf5fc016bb0d991054b$$aNoll, Elisa Marie$$b7
000304988 7001_ $$0P:(DE-He78)ee6ac6f077e7f03250a3c17e3184a9f9$$aGiese, Nathalia$$b8
000304988 7001_ $$0P:(DE-He78)2599296bb9087b2fed9d0e353a8dcdf9$$aYen, Hsi-Yu$$b9
000304988 7001_ $$aSteiger, Katja$$b10
000304988 7001_ $$0P:(DE-He78)03fd0ab6ad061c771968971670c391e2$$aVogel, Vanessa$$b11
000304988 7001_ $$0P:(DE-He78)0812f68beb25392984d3abbe3c58b6d2$$aKlein, Corinna$$b12
000304988 7001_ $$aHackert, Thilo$$b13
000304988 7001_ $$aKoschny, Ronald$$b14
000304988 7001_ $$0P:(DE-He78)14aa02d2ca0515d0c53f1d6678e3ca34$$aOpitz, Christiane A$$b15$$udkfz
000304988 7001_ $$0P:(DE-He78)732f4fbcddb0042251aa759a2e74d3b2$$aTrumpp, Andreas$$b16$$udkfz
000304988 7001_ $$0P:(DE-He78)0f44fcb0b05507b0a20b175f7ba9ed1c$$aSprick, Martin$$b17$$eLast author$$udkfz
000304988 7001_ $$0P:(DE-He78)f185c4fb611183f9ec2258f7a5231bbc$$aRösli, Christoph$$b18$$eLast author
000304988 773__ $$0PERI:(DE-600)2053902-2$$a10.1097/MPA.0000000000002553$$pnn$$tPancreas$$vnn$$x0885-3177$$y2025
000304988 909CO $$ooai:inrepo02.dkfz.de:304988$$pVDB
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6e9ce2232245f76dc483333cba4a5b91$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)067d470839d964b72671ab5d5e2d5a70$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c8c3731ac32efc10657108a8c8ae1fa6$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cdce23b98212f4c0ae5f2c63cf14d9ee$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fdbfe09d9e673c78880ead1e0a7a2063$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7a92d9b96e406e0b3e2444b4383c4dc5$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8a03c8dd68c79f91bfe6594e4d2f97e2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19623ddc45d1abf5fc016bb0d991054b$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ee6ac6f077e7f03250a3c17e3184a9f9$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)03fd0ab6ad061c771968971670c391e2$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0812f68beb25392984d3abbe3c58b6d2$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)14aa02d2ca0515d0c53f1d6678e3ca34$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)732f4fbcddb0042251aa759a2e74d3b2$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0f44fcb0b05507b0a20b175f7ba9ed1c$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000304988 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f185c4fb611183f9ec2258f7a5231bbc$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000304988 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000304988 9141_ $$y2025
000304988 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2024-12-05$$wger
000304988 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000304988 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000304988 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000304988 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-05
000304988 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000304988 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-05
000304988 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-05
000304988 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000304988 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000304988 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000304988 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPANCREAS : 2022$$d2024-12-05
000304988 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-05
000304988 9202_ $$0I:(DE-He78)A010-20160331$$kA010$$lA010 Stammzellen und Krebs$$x0
000304988 9201_ $$0I:(DE-He78)A010-20160331$$kA010$$lA010 Stammzellen und Krebs$$x0
000304988 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x1
000304988 9200_ $$0I:(DE-He78)A010-20160331$$kA010$$lA010 Stammzellen und Krebs$$x0
000304988 980__ $$ajournal
000304988 980__ $$aVDB
000304988 980__ $$aI:(DE-He78)A010-20160331
000304988 980__ $$aI:(DE-He78)MU01-20160331
000304988 980__ $$aUNRESTRICTED